News

May 9, 2023

ESMO Breast Cancer 2023

April 14, 2023

AACR Annual Meeting 2023

December 15, 2022

Longevity Technology – Innovative cancer treatment device has longevity potential

December 15, 2022

Oncology Tube: The LW-02 Cartridge

November 9, 2022

Empowered Patient Podcast with Karen Jagoda -Treating Tumors Using Subtractive Approach to Remove Molecules Suppressing Immune System with Amir Jafri Immunicom

Immunicom Inc.

HEADQUARTERS

San Diego, CA

RESOURCES

Terms of Use

Privacy Policy

FCOI Policy

Instructions for Use

GET IN TOUCH

Contact us

Newsletter Subscription

Immunicom’s Immunopheresis® therapy, including the LW-02 blood-filtering immunotherapy device, has not been approved by the US Food and Drug Administration and is an investigational therapy in all of Immunicom’s ongoing clinical research studies. Immunicom’s LW-02 blood-filtering immunotherapy device has been granted European CE Mark Certification for use in adults with advanced, refractory, triple-negative breast cancer in Europe.